Menu
Eli Lilly and Novo Nordisk executives joined President Donald Trump and other administration officials Nov. 6 in announcing new drug pricing deals for GLP-1s. (Photo courtesy: White House video screen grab)

White House Deal With Eli Lilly, Novo Nordisk to Lower GLP-1 Prices Likely to Affect 340B Program But Extent Unclear

Shannon Young, Associate Editor/Senior Writer 340B Report Views
The Trump administration’s latest agreements with two major drugmakers to lower the cost of expensive weight loss and diabetes drugs, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

State Contract Pharmacy Lawsuit Roundup: New Filings in Colorado and Rhode Island

PhRMA Again Targets 340B Hospitals, PBMs in New Ad 

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live